{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Malignant+Disorders&page=2", "query": { "condition": "Non Malignant Disorders", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Malignant+Disorders&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T14:32:01.146Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933985" }, { "nct_id": "NCT00002471", "title": "Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1990-02", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002471" }, { "nct_id": "NCT00415597", "title": "Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 467, "start_date": "2006-12", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415597" }, { "nct_id": "NCT01118013", "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "donor lymphocytes", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "reduced-intensity transplant conditioning procedure", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 6, "start_date": "2010-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 10, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Elkton MD", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118013" }, { "nct_id": "NCT04678440", "title": "[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lung Cancer, Nonsmall Cell" ], "interventions": [ { "name": "[18F]F-AraG Imaging", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-03-31", "completion_date": "2023-02-07", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678440" }, { "nct_id": "NCT00949052", "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "evaluation of cancer risk factors", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2009-01", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949052" }, { "nct_id": "NCT06362369", "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Melanoma", "Metastasis", "Pleural Mesothelioma", "Renal Cell Carcinoma", "MSI-High", "Mismatch Repair Deficiency", "Colorectal Cancer", "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Renal Cell Cancer", "Kidney Cancer", "Skin Cancer", "Non Small Cell Lung Cancer", "NSCLC", "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations", "ALK Genomic Tumor Aberrations" ], "interventions": [ { "name": "Alintegimod", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "7 Hills Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2024-08-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06362369" }, { "nct_id": "NCT01050439", "title": "Unrelated Donor Transplant for Malignant and Non-Malignant Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Bone Marrow Failure Syndromes", "Immunodeficiencies", "Histiocytosis" ], "interventions": [ { "name": "UDAlloSCT", "type": "PROCEDURE" }, { "name": "Therapy", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 22, "start_date": "2002-11", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01050439" }, { "nct_id": "NCT00126672", "title": "RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonmalignant Neoplasm", "Tuberous Sclerosis", "Lymphangioleimyomatosis", "Kidney Angiomyolipoma" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "3 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2005-12-20", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 7, "location_summary": "Loma Linda, California • Hartford, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126672" }, { "nct_id": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-14", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-10T14:32:01.146Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902040" } ] }